title: Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).
abstract: In this multicenter evaluation, the VERSANT HCV RNA 3.0 Assay (bDNA) (Bayer Diagnostics, Tarrytown, N.Y.) was shown to have excellent reproducibility, linearity, and analytical sensitivity across specimen collection matrices (serum, EDTA, ACD-A), and hepatitis C virus (HCV) genotypes 1 to 6. The VERSANT HCV bDNA Assay has a reportable range of 615 to 7690000 (7.69 x 10(6)) IU/ml. The total coefficient of variation (CV) ranged from 32.4% at 615 IU/ml to 17% at 6.8 x 10(6) IU/ml. The assay was linear across the reportable range. Analytical specificity of 98.8% was determined by testing 999 specimens from volunteer blood donors. Evaluation of HCV genotypes using RNA transcripts of representative clones of 1a, 1b, 2a, 2b, 2c, 3a, 4a, 5a, and 6a and patient specimens showed that the largest difference between genotype 1, upon which the assay is standardized, and non-1 genotypes was within 1.5-fold. Testing of potentially interfering endogenous substances and exogenous substances and conditions found no interference in HCV-positive or HCV-negative specimens except for unconjugated bilirubin at concentrations of >or=20 mg/dl and protein at concentrations of >or=9 g/dl. Biological variability was estimated from 29 clinically stable individuals not on HCV therapy who were tested weekly over an 8-week period. The combined estimate of total (biologic plus assay) variability was 0.15 log(10) standard deviation (CV, 36.1%), a fold change of 2.6. Thus, the observed fold change between any two consecutive HCV RNA measures is expected to be less than 2.6-fold (equivalent to 0.41 log(10) IU/ml) 95% of the time in clinically stable individuals.
authors.affiliation: Department of Laboratory Medicine, University of California, San Francisco 94110, USA. elbeik@itsa.ucsf.edu
authors.forename: Tarek
authors.initials: T
authors.lastname: Elbeik
authors.forename: Johan
authors.initials: J
authors.lastname: Surtihadi
authors.forename: Mark
authors.initials: M
authors.lastname: Destree
authors.forename: Jed
authors.initials: J
authors.lastname: Gorlin
authors.forename: Mark
authors.initials: M
authors.lastname: Holodniy
authors.forename: Saeed A
authors.initials: SA
authors.lastname: Jortani
authors.forename: Ken
authors.initials: K
authors.lastname: Kuramoto
authors.forename: Valerie
authors.initials: V
authors.lastname: Ng
authors.forename: Roland
authors.initials: R
authors.lastname: Valdes
authors.forename: Alexandra
authors.initials: A
authors.lastname: Valsamakis
authors.forename: Norah A
authors.initials: NA
authors.lastname: Terrault
mesh_terms: D021121:Branched DNA Signal Amplification Assay / Q000379:methods*; D016174:Hepacivirus / Q000145:classification / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000097:blood / Q000175:diagnosis / Q000821:virology*; D006801:Humans; D012367:RNA, Viral / Q000097:blood*; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013048:Specimen Handling
chemical_list: D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic